PROSILICO attended IDDST in Tokyo 8-10 May and gave an oral presentation of new ANDROMEDA…

In 49 study comparisons, ANDROMEDA by Prosilico outperformed laboratory methods in 74 % of cases…

PROSILICO participates in the planned SciLifeLab PULSE cofund postdoctoral programme SciLifeLab has the ambition to…

Validation of predicted conformal intervals for prediction of human clinical pharmacokinetics https://www.biorxiv.org/content/10.1101/2022.11.10.515917v1  

ANDROMEDA by Prosilico software successfully predicts human clinical pharmacokinetics of 70 drugs out of reach…

FDA Modernization Act - The bill defines “nonclinical tests or studies ” as a test…

An Analysis of Laboratory Variability and Thresholds for Human in vitro ADME/PK Methods & Prediction…

In vitro to in vivo pharmacokinetic translation guidance https://www.biorxiv.org/content/10.1101/2022.09.26.509470v1

Investigation of Molecular Weights and Pharmacokinetic Characteristics of Older and Modern Small Drugs https://www.biorxiv.org/content/10.1101/2022.09.21.508888v1

Prediction of Biopharmaceutical Characteristics of PROTACs using the ANDROMEDA by Prosilico Software https://www.biorxiv.org/content/10.1101/2022.09.22.509053v1